Neural Analytics, Inc. Raises $15 Million in Series B Financing
Neural Analytics, Inc., a medical device company developing and commercializing technology to measure, diagnose, and track brain health, today announced that it has raised $15 million in Series B financing led by Alpha Edison.
“This round of funding will allow us to build on the momentum we have generated in 2017 and expand our team as we further advance the development of the Lucid System to assess and monitor additional brain health conditions,” said Leo Petrossian, Ph.D., Co-Founder and Chief Executive Officer of Neural Analytics, Inc.
The Lucid Transcranial Doppler Ultrasound System (Lucid System) uses ultrasound to assess the brain’s blood vessels from outside the body. This analysis is non-invasive, can be performed in the physician’s office, and helps the physician diagnose brain disorders. The system is FDA-cleared and CE-marked for the monitoring of blood flow velocities in the cerebral vasculature. The Lucid System is a battery-operated, medical-grade tablet device designed to be transported easily throughout a medical facility and in a range of clinical scenarios that require the rapid assessment of blood flow in the brain to expedite treatment.
“We are committed to investing in companies, such as Neural Analytics, who are making key strides in data-driven diagnostics by marrying AI, machine learning and robotics to existing in-market technologies,” said Nick Grouf, Managing Partner at Alpha Edison. “In the case of brain health management, this facilitates early and accurate diagnosis which is essential to improving patient outcomes. We believe Neural Analytics is impressively positioned to create material value for patients, the broader healthcare ecosystem, and as a consequence, investors.”
This follows Neural Analytics’ recent announcement of its partnership with the Department of Defense (DoD) awarding the company with a $10 million contract to develop and supply a portable, point of injury device for assessing combat-related traumatic brain injury (TBI). The contract was awarded by the U.S. Army Medical Research and Materiel Command.
In addition, this past November the positive results from the first phase of the EXPEDITE program (under an IRB-approved investigation) were presented at the 10th Society of Vascular and Interventional Neurology annual meeting. The first phase of the program was designed to examine the feasibility of Neural Analytics’ Lucid System in the measurement of cerebral blood flow in patients with large vessel occlusion (LVO), a key cause of acute ischemic stroke (AIS). The data presented demonstrated that the company’s Lucid System is capable of measuring and displaying LVO with 91 percent sensitivity and 85 percent specificity as compared to the current standard of care imaging in persons suspected of having a stroke.
About Alpha Edison
Alpha Edison is an early stage venture firm that partners with courageous entrepreneurs to build industry-changing technology platforms. The company shares its research and expertise in business model innovation to help ambitious founders create new markets, unlock latent demand, and scale businesses that change our world - for the better. Based in Los Angeles, CA, you can learn more about Alpha Edison at www.alphaedison.com.
About Neural Analytics, Inc.
Neural Analytics, Inc. was founded in 2013 to create products and services to measure, diagnose, and track brain health. The company’s current focus is on acute ischemic stroke, traumatic brain injury, and dementia. They combine leading data science with cutting edge hardware to allow first responders and clinicians to accurately assess and monitor brain health issues. Their devices are designed to be portable, autonomous, reliable, and produce precise and objective physiological measurements for medical responder monitoring of neural disorders.
More information is available at http://www.neuralanalytics.com.
Neural Analytics, Inc.
Lazar Partners for Neural Analytics, Inc.
Erich Sandoval, +1-917-497-2867
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 23:30 | Tiedote
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 19:00 | Tiedote
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 18:53 | Tiedote
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 16:07 | Tiedote
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
WeQ Launches to Transform Mobile Ad Tech with Human Intelligence and Inclusivity24.4.2018 16:00 | Tiedote
WeQ, a mobile ad tech brand providing user acquisition and engagement services at a global scale, announced today its official launch. WeQ is driven by a forward-thinking, socio-economic movement striving to shift from an exclusive ‘I’ culture to a collaborative ‘We’ culture. Setting its sights on becoming a trusted leader in the mobile ad tech industry, WeQ combines innovative data-driven technology with the collective human intelligence of its accomplished team of mobile ad tech experts to empower companies to reach their goals. WeQ comes out of the gate armed with a strategic investment, having secured more than $50 million USD in internal funds and debt capital to accelerate an ambitious global growth path. The ad tech brand plans to use the funds as it undertakes an aggressive M&A strategy. Over the next 12-24 months, WeQ plans to acquire cutting-edge technologies from innovative ventures to expand its technological footprint and services, attract international talent, and enter n
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 15:17 | Tiedote
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme